Table 2. Clinical characteristics of human lung adenocarcinomas.
| ID | Stageb | Primary Growth Pattern | Principle Inflammatory Cell Typea |
|---|---|---|---|
| 1 | I | Acinar | L |
| 2 | I | Acinar | L |
| 3 | I | Acinar, mucinous | L,AM |
| 4 | II | Acinar | L |
| 5 | II | Acinar | L |
| 6 | II | Mucinous, solid | L |
| 7 | II | Acinar | AM |
| 8 | II | Acinar | L |
| 9 | II | Acinar, mucinous | L,AM |
| 10 | II | Acinar, solid | L |
| 11 | II | Acinar | L,AM |
| 12 | II | Acinar, mucinous | L |
| 13 | II | Acinar | L |
| 14 | II | Acinar | L |
| 15 | III | Solid | L |
| 16 | III | Acinar, solid | AM,L |
| 17 | III | Solid | L |
| 18 | III | Acinar, solid | L,AM |
a. Principle inflammatory cell type present in associated tissue: L=lymphocytes; AM=alveolar macrophages; N= none observed.
b. Tumor Staging based on the Pathologic TNM classification.